Clinical trial / 2011
Aloe vera was not superior to placebo in improving quality of life in patients with irritable bowel syndrome.
In a randomized, double-blind, cross-over study, patients with irritable bowel syndrome were assigned to take 60 mL of Aloe vera or placebo orally twice daily, separated by a washout period. A total of 110 patients were randomized, with 47 completing all questionnaires and both treatment periods. Statistical analysis demonstrated no difference in quality of life outcomes between Aloe vera and placebo. Authors noted that dropouts and other confounding factors may have affected the study's power to detect a clinically meaningful difference.
- Study type
- Multicenter, randomized, double-blind, cross-over placebo-controlled trial
- Who was studied
- 110 patients with irritable bowel syndrome randomized (47 completed both arms and all questionnaires)
- What was measured
- Quality of life measured by Gastrointestinal Symptoms Rating Score, IBS Quality of Life, EuroQol, and SF-12
THE PAPER
A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life.
Hutchings HA, Wareham K, Baxter JN, Atherton P, Kingham JG, Duane P, Thomas L, Thomas M, Ch'ng CL, Williams JG. ISRN Gastroenterol, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.